Patents by Inventor Zhengchao Tu

Zhengchao Tu has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10683278
    Abstract: Provided are a substituted quinolone derivative as shown by formula (I), or a pharmaceutically acceptable salt and a prodrug molecule thereof, and a pharmaceutical composition thereof, as well as the use of same in preparing drugs for the prevention and treatment of a tumor. The quinolone derivative, salt, prodrug molecule, and pharmaceutical composition thereof can be used as a protein kinase inhibitor, which is effective in inhibiting the activity of AXL protein kinase, and is capable of inhibiting the proliferation, migration and invasion of various tumor cells; and can be used in the preparation of anti-tumor drugs, especially drugs for treating hyperproliferative diseases such as a tumor in human beings and other mammals.
    Type: Grant
    Filed: August 18, 2016
    Date of Patent: June 16, 2020
    Assignees: SHANGHAI HAIHE PHARMACEUTICAL CO., LTD., JINAN UNIVERSITY, SHANGHAI INTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES
    Inventors: Ke Ding, Meiyu Geng, Li Tan, Jian Ding, Zhang Zhang, Jing Ai, Xiaomei Ren, Donglin Gao, Zhengchao Tu, Xiaoyun Lu, Dongmei Zhang
  • Publication number: 20200017491
    Abstract: Fibroblast Growth Factor Receptor kinase inhibitors and prodrugs thereof of Formula (I) and their use for the treatment of hyper-proliferative diseases such as retinopathy, psoriasis, rheumatoid arthritis, osteoarthritis, septic arthritis, tumour metastasis, periodontal disease, corral ulceration, proteinuria, coronary thrombosis from atherosclerotic plaque, aneurismal aorta, dystrophobic epidermolysis bullosa, degenerative cartilage loss following traumatic joint injury, osteopenias mediated by MMP activity, tempero mandibular joint disease, and demyelating disease of the nervous system.
    Type: Application
    Filed: March 2, 2018
    Publication date: January 16, 2020
    Applicants: Auckland Uniservices Limited, Guangzhou Intitute of BioMedicine and Health
    Inventors: Adam Vorn PATTERSON, Jeffrey Bruce SMAILL, Amir ASHOORZADEH, Christopher Paul GUISE, Christopher John SQUIRE, Swarnalatha Akuratiya GAMAGE, Maria Rosaria ABBATTISTA, Matthew Roy BULL, Angus Cheverton GREY, Xueqiang LI, Ke DING, Xiaomei REN, Shuang JIANG, Zhengchao TU
  • Publication number: 20190367465
    Abstract: A heterocyclic urea compound, and specifically discloses an indoleamine-2,3-dioxygenase inhibitor of a heterocyclic urea compound, which solves the problems of weak curative effect and larger toxic and side effects of existing immunological therapy drugs. The invention further provides a preparation method for an indoleamine-2,3-dioxygenase inhibitor of a heterocyclic urea compound, and an application of the indoleamine-2,3-dioxygenase inhibitor of a heterocyclic urea compound or a pharmaceutically acceptable salt thereof in preparing drugs for treating or preventing tumors.
    Type: Application
    Filed: January 1, 2018
    Publication date: December 5, 2019
    Inventors: Sheng JIANG, Zhengchao TU, Haiping HAO, Hequan YAO, Yatao QIU, Yiwu YAO, Dong CHEN
  • Patent number: 10370360
    Abstract: Compounds of formula (I), their pharmaceutically acceptable salts and stereoisomers thereof, as well as application in effectively inhibiting the enzymatic activity of discoidin domain receptor 1 and can be used as new therapeutic agents for preventing and treating e.g. inflammation, liver fibrosis, kidney fibrosis, lung fibrosis, skin scar, atherosclerosis, and cancer. The compound of formula I is: wherein the variables are as defined herein.
    Type: Grant
    Filed: October 21, 2015
    Date of Patent: August 6, 2019
    Assignees: The Board of Regents of the University of Texas System, Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences
    Inventors: Rolf A. Brekken, Ke Ding, Xiaomei Ren, Zhengchao Tu, Zhen Wang, Kristina Y. Aguilera
  • Patent number: 10155756
    Abstract: Disclosed in the disclosure are a pyrazolo [1,5-a] pyrideine compound with structural features as shown in formula (I) or a pharmaceutically acceptable salt, stereoisomer or prodrug molecule thereof and a use thereof. Such compounds have a good in vitro antituberculosis activity, and the minimal inhibitory concentration (MIC) of the compounds is lower than 0.1 ?g/mL and partially achieves 0.01 ?g/mL, and have a very strong inhibiting effect on clinically selected multi-drug resistant tuberculosis (MDR-TB) strains. In an in vivo experiment, the pyrazolo[1,5-a] pyrideine compounds of the present disclosure can effectively scavenge the infectious dose of H37Ra in a mouse body at 20 mg/kg/d does, thereby being a new type of antituberculosis compound.
    Type: Grant
    Filed: August 13, 2015
    Date of Patent: December 18, 2018
    Assignee: Guangzhou Eggbio Co., Ltd.
    Inventors: Xiaoyun Lu, Jian Tang, Ke Ding, Tianyu Zhang, Xiantao Zhang, Zhengchao Tu, Tian Wu, Junting Wan, Yuanyuan Cao, Shengjiang He
  • Publication number: 20180265496
    Abstract: Provided are a substituted quinolone derivative as shown by formula (I), or a pharmaceutically acceptable salt and a prodrug molecule thereof, and a pharmaceutical composition thereof, as well as the use of same in preparing drugs for the prevention and treatment of a tumor. The quinolone derivative, salt, prodrug molecule, and pharmaceutical composition thereof can be used as a protein kinase inhibitor, which is effective in inhibiting the activity of AXL protein kinase, and is capable of inhibiting the proliferation, migration and invasion of various tumor cells; and can be used in the preparation of anti-tumor drugs, especially drugs for treating hyperproliferative diseases such as a tumor in human beings and other mammals.
    Type: Application
    Filed: August 18, 2016
    Publication date: September 20, 2018
    Applicants: JINAN UNIVERSITY, SHANGHAI INSTITUTE OF MATERIA MEDICA,CHINESE ACADEMY OF SCIENCES
    Inventors: Ke DING, Meiyu GENG, Li TAN, Jian DING, Zhang ZHANG, Jing AI, Xiaomei REN, Donglin GAO, Zhengchao TU, Xiaoyun LU, Dongmei ZHANG
  • Patent number: 10059694
    Abstract: Disclosed are a 2-aminopyrimidine compound and pharmaceutical composition and use thereof. The structure of the 2-aminopyrimidine compound is as represented by formula I, in the formula, R1, R2, R3, R4, R5, X, Y, Z, W, (i) being as defined in the specification and the claims. Such compounds effectively inhibit the growth of a variety of tumor cells and have inhibitory effects on EGFR and IGF1R protease, and can be used for preparing antineoplastic drugs and overcome the tolerance induced by the existing drugs such as gefitinib, erlotinib and the like. The compound has selectivity for tumors, in particular the wild-type non-small cell lung cancer and have good pharmacokinetic characteristics.
    Type: Grant
    Filed: November 18, 2015
    Date of Patent: August 28, 2018
    Assignees: Shanghai Institute of Materia Medica, Chinese Academy of Sciences, GUANGZHOU INSTITUTES OF BIOMEDICINE AND HEALTH, CHINESE ACADEMY OF SCIENCES
    Inventors: Ke Ding, Jian Ding, Shingpan Chan, Meiyu Geng, Xiaomei Ren, Hua Xie, Zhengchao Tu, Yi Chen
  • Publication number: 20180022730
    Abstract: Compounds of formula (I), their pharmaceutically acceptable salts and stereoisomers thereof, as well as application in effectively inhibiting the enzymatic activity of discoidin domain receptor 1 and can be used as new therapeutic agents for preventing and treating e.g. inflammation, liver fibrosis, kidney fibrosis, lung fibrosis, skin scar, atherosclerosis, and cancer. The compound of formula I is: wherein the variables are as defined herein.
    Type: Application
    Filed: October 21, 2015
    Publication date: January 25, 2018
    Inventors: Rolf A. BREKKEN, Ke DING, Xiaomei REN, Zhengchao TU, Zhen WANG, Kristina Y. AGUILERA
  • Publication number: 20170313697
    Abstract: Disclosed in the disclosure are a pyrazolo[1,5-a]pyrideine compound with structural features as shown in formula (I) or a pharmaceutically acceptable salt, stereoisomer or prodrug molecule thereof and a use thereof. Such compounds have a good in vitro antituberculosis activity, and the minimal inhibitory concentration (MIC) of the compounds is lower than 0.1 ?g/mL and partially achieves 0.01 ?g/mL, and have a very strong inhibiting effect on clinically selected multi-drug resistant tuberculosis (MDR-TB) strains. In an in vivo experiment, the pyrazolo[1,5-a]pyrideine compounds of the present disclosure can effectively scavenge the infectious dose of H37Ra in a mouse body at 20 mg/kg/d does, thereby being a new type of antituberculosis compound.
    Type: Application
    Filed: August 13, 2015
    Publication date: November 2, 2017
    Inventors: Xiaoyun Lu, Jian Tang, Ke Ding, Tianyu Zhang, Xiantao Zhang, Zhengchao Tu, Tian Wu, Junting Wan, Yuanyuan Cao, Shengjiang He
  • Publication number: 20170283398
    Abstract: Disclosed are a 2-aminopyrimidine compound and pharmaceutical composition and use thereof. The structure of the 2-aminopyrimidine compound is as represented by formula I, in the formula, R1, R2, R3, R4, R5, X, Y, Z, W, (i) being as defined in the specification and the claims. Such compounds effectively inhibit the growth of a variety of tumor cells and have inhibitory effects on EGFR and IGF1R protease, and can be used for preparing antineoplastic drugs and overcome the tolerance induced by the existing drugs such as gefitinib, erlotinib and the like. The compound has selectivity for tumors, in particular the wild-type non-small cell lung cancer and have good pharmacokinetic characteristics.
    Type: Application
    Filed: November 18, 2015
    Publication date: October 5, 2017
    Applicants: Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences, GUANGZHOU INSTITUTES OF BIOMEDICINE AND HEALTH, CHINESE ACADEMY OF SCIENCES
    Inventors: Ke Ding, Jian Ding, Shingpan Chan, Meiyu Geng, Xiaomei Ren, Hua Xie, Zhengchao Tu, Yi Chen
  • Patent number: 9770432
    Abstract: The present invention discloses deuterated benzopyran compounds having structure features as shown in Formula (I), or pharmaceutically acceptable salts or stereoisomers thereof, or prodrug molecules thereof. With excellent anti-inflammatory and analgesic effects and the capability to inhibit growth of tumor cells, such compounds are novel COX-2 selective inhibitors. The compounds and pharmaceutically acceptable salts thereof disclosed by the present application can be applied in preparing anti-inflammatory and analgesic drugs and drugs for treating or preventing tumors.
    Type: Grant
    Filed: June 14, 2016
    Date of Patent: September 26, 2017
    Assignee: Guangzhou Institutes of Biomedicine And Health, Chinese Academy of Sciences
    Inventors: Yanmei Zhang, John Jeffrey Talley, Mark G. Obukowicz, Zhengchao Tu, Micky Tortorella, Yican Wang, Jianqi Liu, Yan Chen, Xiaorong Liu, Xin Lu
  • Patent number: 9763914
    Abstract: The present invention discloses deuterated benzopyran compounds having structure features as shown in Formula (I), or pharmaceutically acceptable salts or stereoisomers thereof, or prodrug molecules thereof. With excellent anti-inflammatory and analgesic effects and the capability to inhibit growth of tumor cells, such compounds are novel COX-2 selective inhibitors. The compounds and pharmaceutically acceptable salts thereof disclosed by the present application can be applied in preparing anti-inflammatory and analgesic drugs and drugs for treating or preventing tumors.
    Type: Grant
    Filed: June 14, 2016
    Date of Patent: September 19, 2017
    Assignee: Guangzhou Institutes of Biomedicine And Health, Chinese Academy of Sciences
    Inventors: Yanmei Zhang, John Jeffrey Talley, Mark G. Obukowicz, Zhengchao Tu, Micky Tortorella, Yican Wang, Jianqi Liu, Yan Chen, Xiaorong Liu, Xin Lu
  • Publication number: 20170020843
    Abstract: The present invention discloses deuterated benzopyran compounds having structure features as shown in Formula (I), or pharmaceutically acceptable salts or stereoisomers thereof, or prodrug molecules thereof. With excellent anti-inflammatory and analgesic effects and the capability to inhibit growth of tumor cells, such compounds are novel COX-2 selective inhibitors. The compounds and pharmaceutically acceptable salts thereof disclosed by the present application can be applied in preparing anti-inflammatory and analgesic drugs and drugs for treating or preventing tumors.
    Type: Application
    Filed: June 14, 2016
    Publication date: January 26, 2017
    Inventors: Yanmei ZHANG, John Jeffrey TALLEY, Mark G. OBUKOWICZ, Zhengchao TU, Micky TORTORELLA, Yican WANG, Jianqi LIU, Yan CHEN, Xiaorong LIU, Xin LU
  • Publication number: 20160287556
    Abstract: The present invention discloses deuterated benzopyran compounds having structure features as shown in Formula (I), or pharmaceutically acceptable salts or stereoisomers thereof, or prodrug molecules thereof. With excellent anti-inflammatory and analgesic effects and the capability to inhibit growth of tumor cells, such compounds are novel COX-2 selective inhibitors. The compounds and pharmaceutically acceptable salts thereof disclosed by the present application can be applied in preparing anti-inflammatory and analgesic drugs and drugs for treating or preventing tumors.
    Type: Application
    Filed: June 14, 2016
    Publication date: October 6, 2016
    Inventors: Yanmei ZHANG, John Jeffrey TALLEY, Mark G. OBUKOWICZ, Zhengchao TU, Micky TORTORELLA, Yican WANG, Jianqi LIU, Yan CHEN, Xiaorong LIU, Xin LU
  • Patent number: 9371305
    Abstract: The present invention discloses deuterated benzopyran compounds having structure features as shown in Formula (I), or pharmaceutically acceptable salts or stereoisomers thereof, or prodrug molecules thereof. With excellent anti-inflammatory and analgesic effects and the capability to inhibit growth of tumor cells, such compounds are novel COX-2 selective inhibitors. The compounds and pharmaceutically acceptable salts thereof disclosed by the present application can be applied in preparing anti-inflammatory and analgesic drugs and drugs for treating or preventing tumors.
    Type: Grant
    Filed: August 10, 2012
    Date of Patent: June 21, 2016
    Assignee: Guangzhou Institutes of Biomedicine And Health, Chinese Academy of Sciences
    Inventors: Yanmei Zhang, John Jeffrey Talley, Mark G. Obukowicz, Zhengchao Tu, Micky Tortorella, Yican Wang, Jianqi Liu, Yan Chen, Xiaorong Liu, Xin Lu
  • Publication number: 20150133538
    Abstract: The present invention discloses deuterated benzopyran compounds having structure features as shown in Formula (I), or pharmaceutically acceptable salts or stereoisomers thereof, or prodrug molecules thereof. With excellent anti-inflammatory and analgesic effects and the capability to inhibit growth of tumor cells, such compounds are novel COX-2 selective inhibitors. The compounds and pharmaceutically acceptable salts thereof disclosed by the present application can be applied in preparing anti-inflammatory and analgesic drugs and drugs for treating or preventing tumors.
    Type: Application
    Filed: August 10, 2012
    Publication date: May 14, 2015
    Applicant: Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences
    Inventors: Yanmei Zhang, John Jeffrey Talley, Mark G. Obukowicz, Zhengchao Tu, Micky Tortorella, Yican Wang, Jianqi Liu, Yan Chen, Xiaorong Liu, Xin Lu
  • Publication number: 20140296216
    Abstract: A compound of formula (I) or (II) and use of the compound in the preparation of drugs for treating cancer are disclosed. The study shows that the compounds can inhibit the growth of many kinds of tumor cells, can be used for targeting epidermal growth factor receptor (EGFR), and particularly can inhibit tumor cells with single or multiple mutations of EGFR (T790M). Therefore, the compound can be used as EGFR inhibitor to treat cancer and has a relatively large application value.
    Type: Application
    Filed: December 21, 2011
    Publication date: October 2, 2014
    Applicant: GUANGZHOU INSTITUTE OF BIOMEDICINE AND HEALTH, CHINESE ACADEMY OF SCIENCES
    Inventors: Ke Ding, Shaohua Chang, Shilin Xu, Lianwen Zhang, Zhengchao Tu, Jian Ding, Meiyu Geng, Yi Chen